Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Charles River Laboratories International (MIL:1CRL) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Charles River Laboratories International Receivables Turnover Related Terms
Charles River Laboratories International Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Charles River Laboratories International Receivables Turnover Chart
Charles River Laboratories International Annual Data
MIL:1CRL vs RVTY, QGEN, ICLR: Receivables Turnover Comparison
For the Diagnostics & Research subindustry, Charles River Laboratories International's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Charles River Laboratories International Receivables Turnover vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Charles River Laboratories International's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Charles River Laboratories International's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Charles River Laboratories International (MIL:1CRL) has a Receivables Turnover of 1.94 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Charles River Laboratories International and its competitors. According to the industry distribution chart, Charles River Laboratories International ranks #58 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 28.7%.
Is Charles River Laboratories International's Receivables Turnover too high?
Charles River Laboratories International's current Receivables Turnover is 1.94. The Medical Diagnostics & Research industry median Receivables Turnover is 5.38. Charles River Laboratories International's value of 1.94 is 63.9% below this industry median. Based on the distribution chart, Charles River Laboratories International ranks #58 out of 202 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Charles River Laboratories International has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does Charles River Laboratories International's Receivables Turnover compare to RVTY and QGEN?
According to the Medical Diagnostics & Research industry distribution chart, Charles River Laboratories International ranks #58 out of 202 companies for Receivables Turnover. This puts Charles River Laboratories International in the upper half of its industry. The industry median Receivables Turnover is 5.38. Charles River Laboratories International's value of 1.94 is 63.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Diagnostics & Research company?
The median Receivables Turnover among Medical Diagnostics & Research companies is 5.38, based on 202 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Charles River Laboratories International's current Receivables Turnover of 1.94 is 63.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Charles River Laboratories International and its competitors. For the Medical Diagnostics & Research industry, the median Receivables Turnover is 5.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Charles River Laboratories International's current Receivables Turnover is 1.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Charles River Laboratories International stock overvalued right now?
Charles River Laboratories International (MIL:1CRL) has a current Receivables Turnover of 1.94. The stock's GF Value™ is €124.51, compared to a current price of €143.90 — trading 15.6% above its estimated fair value. The current Receivables Turnover is 1.94 and 63.9% below the Medical Diagnostics & Research industry median of 5.38. Charles River Laboratories International's overall GF Score™ is 69/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Charles River Laboratories International (MIL:1CRL), the current Receivables Turnover is 1.94 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Charles River Laboratories International (MIL:1CRL) Overvalued in 2026?
Based on GuruFocus' analysis, Charles River Laboratories International stock appears to be overvalued.
The current stock price of €143.90 is trading 15.6% above its estimated GF Value™ of €124.51.
Key valuation signals for MIL:1CRL:
Receivables Turnover: 1.94
GF Value™: €124.51 vs. price of €143.90 (15.6% above fair value)
Industry Position: 63.9% below the Medical Diagnostics & Research median (#58 of 202)
No single metric tells the full story. See the MIL:1CRL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Charles River Laboratories International Business Description
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
69GF Score
Get the complete analysis for MIL:1CRL
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:1CRL has been successfully added to your 
